Merck, Inc.
🇵🇭Philippines
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
Phase 2
Completed
- Conditions
- HPV Infections
- Interventions
- Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- First Posted Date
- 2006-09-20
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1021
- Registration Number
- NCT00378560
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
Phase 3
Completed
- Conditions
- HypercholesteremiaHyperlipidemia
- Interventions
- Drug: MK-0524ADrug: ER NiacinDrug: Placebo
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 825
- Registration Number
- NCT00376584
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
- Conditions
- HIV Infections
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00377065
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT00373490
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: sitagliptin phosphate
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 134
- Registration Number
- NCT00372060
PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)
Phase 3
Completed
- Conditions
- Hepatitis B, Chronic (CHB)
- Interventions
- Biological: Pegylated interferon alfa-2b (PegIntron)Drug: Adefovir dipivoxil (adefovir)
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT00371761
MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 126
- Registration Number
- NCT00371007
A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: MK-0518
- First Posted Date
- 2006-08-30
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 566
- Registration Number
- NCT00369941
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
Phase 3
Completed
- Conditions
- Arthritis, Psoriatic
- Interventions
- Drug: Methotrexate (MTX)Drug: Infliximab + methotrexate (IFX + MTX)
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 115
- Registration Number
- NCT00367237
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
Phase 2
Completed
- Conditions
- Papillomavirus InfectionsGenital Diseases, Female
- Interventions
- Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80Biological: Placebo (mcg) (Aluminum Adjuvant) 450Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20Biological: Placebo (mcg) (Aluminum Adjuvant)225
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1158
- Registration Number
- NCT00365716
© Copyright 2025. All Rights Reserved by MedPath